Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

India flag India · Delayed Price · Currency is INR
211.81
-0.45 (-0.21%)
May 20, 2025, 1:29 PM IST
46.66%
Market Cap 14.10B
Revenue (ttm) 2.69B
Net Income (ttm) 553.61M
Shares Out 66.44M
EPS (ttm) 8.22
PE Ratio 25.82
Forward PE n/a
Dividend 2.50 (1.17%)
Ex-Dividend Date Sep 6, 2024
Volume 46,421
Average Volume 385,715
Open 214.99
Previous Close 212.26
Day's Range 211.00 - 214.99
52-Week Range 110.00 - 328.04
Beta 0.42
RSI 44.95
Earnings Date May 19, 2025

About Jagsonpal Pharmaceuticals

Jagsonpal Pharmaceuticals Limited engages in the manufacturing, selling, and trading of pharmaceutical products and active pharmaceutical ingredients in India and internationally. It offers pharmaceutical formulations and products in the areas of gynaecology, orthopaedics, dermatology, and paediatrics. The company provides drugs in the form of tablets, softgels, injections, capsules, and syrups. It serves health care professionals and government institutions. Jagsonpal Pharmaceuticals Limited was incorporated in 1978 and is based in Gurugram, I... [Read more]

Sector Healthcare
Founded 1978
Employees 1,025
Stock Exchange National Stock Exchange of India
Ticker Symbol JAGSNPHARM
Full Company Profile

Financial Performance

In 2024, Jagsonpal Pharmaceuticals's revenue was 2.69 billion, an increase of 28.76% compared to the previous year's 2.09 billion. Earnings were 553.61 million, an increase of 146.45%.

Financial Statements

News

Jagsonpal Pharmaceuticals shares drop 2.6% after USFDA issues warning letter for manufacturing lapses at API plant

Jagsonpal Pharmaceuticals shares fell over 2% after the US Food and Drug Administration (USFDA) issued a warning letter citing significant manufacturing lapses at its Rajasthan-based active pharmaceut...

3 months ago - Business Upturn

Jagsonpal Pharmaceuticals acquires Resilient Cosmeceuticals’ India business for Rs 24 crore

Jagsonpal Pharmaceuticals Limited (BSE: 507789, NSE: JAGSNPHARM) has announced the acquisition of Resilient Cosmeceuticals Private Limited’s India business for ₹24 crore. The deal, funded through inte...

3 months ago - Business Upturn

Jagsonpal Pharmaceuticals shares jump nearly 6% on strong Q3 FY25 results

Jagsonpal Pharmaceuticals Limited shares surged nearly 6% on January 23, 2025, following the announcement of its robust Q3 FY25 financial performance. The stock traded at ₹241, up by ₹12.75, reflectin...

4 months ago - Business Upturn

Jagsonpal Pharmaceuticals block trade: 22 lakh shares exchanged in ₹88 crore deal

On September 6, 2024, JAGSNPHARM witnessed a significant block trade during Session 1, with 22,00,000 shares exchanging hands at a steady price of ₹400.00. Despite the large transaction, the stock clo...

8 months ago - Business Upturn